APLT Share Price | Applied Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Applied Therapeutics, Inc.?

Market Cap: As of Jun 18, Applied Therapeutics, Inc. has a market capitalization of 48.84 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Applied Therapeutics reported net sales of 0.26 million and a net profit of -43.50 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 57.01 million and total assets of 86.69 million.

Q: What does Applied Therapeutics, Inc. do?

Overview:Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates targeting unmet medical needs in the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025)Market cap: USD 48.84 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.37Return on Equity: -287.00%Price to Book: 1.33Contact Details:Address: 545 5TH AVENUE, SUITE 1400, NEW YORK NY: 10017Tel: 1 212 2209319Fax: 1 302 6365454Website: http://www.appliedtherapeutics.com/

Q: Is Applied Therapeutics, Inc. overvalued or undervalued?

As of 7 August 2024, the valuation grade for Applied Therapeutics, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its negative performance metrics, including a Price to Book Value of 1.43 and an EV to Sales ratio of 1.93, despite being a loss-making entity with a P/E ratio that cannot be calculated. The ROE stands at a staggering -287.00%, further emphasizing the company's struggles.In comparison to its peers, Applied Therapeutics shows a stark contrast with Fusion Pharmaceuticals, Inc. and Zevra Therapeutics, both classified as risky, with P/E ratios of -17.58 and -5.05, respectively. The overall peer group reflects a challenging environment, with most companies also facing negative valuations. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date decline of 64.96% compared to a modest gain of 2.44% for the index, reinforcing the notion that Applied Therapeutics is currently overvalued.

Q: Is Applied Therapeutics, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Applied Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the monthly timeframe, bearish moving averages on the daily timeframe, and a bearish RSI on the weekly timeframe. Additionally, the KST and OBV show mixed signals, with the weekly indicators being bullish while the monthly indicators are bearish. In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -48.00% compared to the S&P 500's 12.22%, and a one-year return of -94.33% versus 17.14% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Sep 2025)

FII

9.05%

Held by 60 FIIs

DII

59.6%

Held by 36 DIIs

Promoter

7.72%

How big is Applied Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Applied Therapeutics, Inc. has a market capitalization of 48.84 million, with net sales of 0.26 million and a net profit of -43.50 million over the latest four quarters. The company reported shareholder's funds of 57.01 million and total assets of 86.69 million as of Dec 24.

View full answer

What does Applied Therapeutics, Inc. do?

22-Jun-2025

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. As of March 2025, it has a market cap of $48.84 million and reported a net profit loss of $22 million.

View full answer

Who are in the management team of Applied Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Applied Therapeutics, Inc. includes Ms. Shoshana Shendelman as Chairman, President, CEO, and Founder, with Dr. Teena Lerner as Lead Independent Director and several Independent Directors including Mr. Leslie Funtleyder, Ms. Stacy Kanter, Mr. Joel Marcus, and Dr. Jay Skyler.

View full answer

Is Applied Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 7, 2024, Applied Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a negative ROE of -287.00% and a year-to-date stock decline of 64.96%, contrasting sharply with its peers and the S&P 500.

View full answer

Is Applied Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Applied Therapeutics, Inc. is in a bearish trend, indicated by bearish MACD, moving averages, and RSI, while significantly underperforming the S&P 500 with a year-to-date return of -48.00% compared to the benchmark's 12.22%.

View full answer

Compare Applied Therapeutics, Inc. with Similar Stocks

Zevra Therapeutics, Inc.XOMA Corp.Zomedica Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -176.30% of over the last 5 years

Positive results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 15 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

11.48

Return on Equity

9,637.30%

Price to Book

-14.63

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Sep 2025)

Net Profit:

-19 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-79.89%

6 Months

-91.49%

1 Year

-97.98%

2 Years

-92.99%

3 Years

-92.64%

4 Years

-99.55%

5 Years

-99.76%

Applied Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.29%

EBIT Growth (5y)

-176.30%

EBIT to Interest (avg)

-86.92

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.37

Sales to Capital Employed (avg)

-0.86

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

89.33%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.43

EV to EBIT

-0.02

EV to EBITDA

-0.02

EV to Capital Employed

-0.14

EV to Sales

1.93

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-287.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (23.63%)

Foreign Institutions

Held by 60 Foreign Institutions (9.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 900.00% vs 0.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 72.30% vs -61.79% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.10",
          "chgp": "900.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.60",
          "val2": "-29.60",
          "chgp": "43.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "-40.20",
          "chgp": "94.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.00",
          "val2": "-68.60",
          "chgp": "72.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,758.00%",
          "val2": "-243,795.10%",
          "chgp": "22,703.71%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -95.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.85% vs -45.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "10.00",
          "chgp": "-95.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.90",
          "val2": "-64.20",
          "chgp": "-61.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "-56.60",
          "chgp": "91.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-105.60",
          "val2": "-119.80",
          "chgp": "11.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-229,228.60%",
          "val2": "-6,458.00%",
          "chgp": "-22,277.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

1.00

0.10

900.00%

Operating Profit (PBDIT) excl Other Income

-16.60

-29.60

43.92%

Interest

0.00

Exceptional Items

-2.40

-40.20

94.03%

Consolidate Net Profit

-19.00

-68.60

72.30%

Operating Profit Margin (Excl OI)

-16,758.00%

-243,795.10%

22,703.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 900.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 72.30% vs -61.79% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

10.00

-95.00%

Operating Profit (PBDIT) excl Other Income

-103.90

-64.20

-61.84%

Interest

0.00

Exceptional Items

-4.80

-56.60

91.52%

Consolidate Net Profit

-105.60

-119.80

11.85%

Operating Profit Margin (Excl OI)

-229,228.60%

-6,458.00%

-22,277.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -95.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.85% vs -45.21% in Dec 2023

All Annual Results

Company CV

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Company Coordinates

Company Details

545 5TH AVENUE, SUITE 1400 , NEW YORK NY : 10017

Tel: 1 212 2209319

http://www.appliedtherapeutics.com/

Registrar Details

Applied Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Applied Therapeutics, Inc.?

Watch in Real-Time

What does Applied Therapeutics, Inc. do?

Who are in the management team of Applied Therapeutics, Inc.?

Is Applied Therapeutics, Inc. overvalued or undervalued?

Is Applied Therapeutics, Inc. technically bullish or bearish?

Compare Applied Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -176.30% of over the last 5 years

Positive results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Applied Therapeutics, Inc.

Company Coordinates